Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Pipeline Pioneers
  • Published:

Vismodegib

Nature Reviews Drug Discovery volume 11, pages 437–438 (2012)Cite this article

Subjects

In January 2012, vismodegib (Erivedge; Curis/Genentech), a small-molecule inhibitor of the Hedgehog signalling pathway, was approved by the US Food and Drug Administration (FDA) for the treatment of basal cell carcinoma (BCC).

BCC is a common form of skin cancer, largely caused by exposure to ultraviolet radiation1. Although most cases are curable by surgery, if the disease progresses to unresectable locally advanced or metastatic forms it can be life-threatening1.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Hedgehog signalling pathway and vismodegib.

References

  1. Rubin, A. I., Chen, E. H. & Ratner, D. R. Basal-cell carcinoma. N. Engl. J. Med. 353, 2262–2269 (2005).

    Article  CAS  Google Scholar 

  2. Barakat, M. T., Humke, E. W. & Scott, M. P. Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer. Trends Mol. Med. 16, 337–348 (2010).

    Article  CAS  Google Scholar 

  3. Robarge, K. D. et al. GDC-0449 — a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19, 5576–5581 (2009).

    Article  CAS  Google Scholar 

  4. US Food and Drug Administration. FDA labeling information — Erivedge. FDA website [online], (2012).

  5. Von Hoff, D. D. et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361, 1164–1172 (2009).

    Article  CAS  Google Scholar 

  6. Skvara, H. et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a Smoothened inhibitor. J. Invest. Dermatol. 131, 1735–1744 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Andrzej Dlugosz is at the University of Michigan Comprehensive Cancer Center, Room 3316, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109-5932, USA.,

    Andrzej Dlugosz

  2. Sid Agrawal is at IMS Consulting Group, 200 Campus Drive, Collegeville, Pennsylvania 19426, USA.,

    Sid Agrawal

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.,

    Peter Kirkpatrick

Authors
  1. Andrzej Dlugosz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sid Agrawal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Andrzej Dlugosz, Sid Agrawal or Peter Kirkpatrick.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dlugosz, A., Agrawal, S. & Kirkpatrick, P. Vismodegib. Nat Rev Drug Discov 11, 437–438 (2012). https://doi.org/10.1038/nrd3753

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3753

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer